Coherus Biosciences completes divestiture of UDENYCA franchise

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals pursuant to the asset purchase agreement dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million. Coherus received an upfront payment of $483.4 million, including $118.4 million for UDENYCA inventory, and is eligible to receive potential milestone payments of up to $75 million. At the closing of the Transaction, which occurred on April 11, 2025, Coherus received an upfront cash payment of $483.4 million, subject to certain adjustments that will be finalized following the closing pursuant to the Agreement. After the closing, Coherus is eligible to receive two milestone payments totaling $75.0 million if Intas meets specified thresholds of net sales of UDENYCA. At the closing, Intas received identified assets related to the UDENYCA franchise, including the UDENYCA pre-filled syringe, the UDENYCA autoinjector, and UDENYCA ONBODY, and assumed identified liabilities. At the closing, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, focused on the development of oncology, immunology, and critical care therapies, assumed full responsibility for the UDENYCA franchise in the U.S.